• 5 things to watch on the ASX 200 on Wednesday

    After a strong start to the week, the S&P/ASX 200 Index (ASX: XJO) gave back some of its gains and dropped notably lower on Tuesday. The benchmark index fell 0.6% to 5,941.1 points.

    Will the market be able to bounce back on Tuesday? Here are five things to watch:

    ASX 200 to rebound.

    It looks set to be a positive day of trade for the ASX 200 index on Wednesday after a very strong night of trade on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 30 points or 0.5% higher. In the United States the Dow Jones rose 2.1%, the S&P 500 climbed 1.3%, and the Nasdaq pushed 0.9% higher. Easing coronavirus cases in Florida and California appears to have given investor sentiment a boost.

    Oil prices rise.

    Energy producers Beach Energy Ltd (ASX: BPT) and Oil Search Limited (ASX: OSH) could be positive performers on Wednesday after oil prices pushed higher. According to Bloomberg, the WTI crude oil price has risen 1% to US$40.49 a barrel and the Brent crude oil price climbed 0.7% to US$43.05 a barrel. Oil prices rose after OPEC and its allies revealed that they cut production by more than agreed in June.

    Gold price largely flat.

    Gold miners such as Newcrest Mining Limited (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) could have a subdued day of trade after a flat night of trade for the gold price. According to CNBC, the spot gold price is ever so slightly higher at US$1,812.50 an ounce. Coronavirus concerns has helped drive the precious metal beyond US$1,800 an ounce this month.

    Woodside asset review.

    The Woodside Petroleum Limited (ASX: WPL) share price could come under pressure on Wednesday after the energy producer announced billions of dollars of impairments. According to the release, Woodside expects to recognise non-cash, post-tax impairment losses of US$3.92 billion with its first half results. This comprises $2.76 billion for oil and gas properties and $1.16 billion for exploration and evaluation assets.

    Collins Foods goes ex-dividend.

    The Collins Foods Ltd (ASX: CKF) share price is likely to drop lower this morning when it trades ex-dividend for its final dividend. Eligible shareholders of the KFC and Taco Bell restaurant operator can now look forward to being paid its fully franked 10.5 cents per share dividend later this month on 30 July 2020.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro owns shares of Collins Foods Limited. The Motley Fool Australia has recommended Collins Foods Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 5 things to watch on the ASX 200 on Wednesday appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/32uJ4tB

  • Texas Man’s Alleged Use of PPP Funds for Crypto Instead of BBQ Has Feds Asking ‘Where’s the Beef?’

    Texas Man’s Alleged Use of PPP Funds for Crypto Instead of BBQ Has Feds Asking ‘Where’s the Beef?’Investigators could not find any online reviews, any documented employees or any established bank account for the defendant's purported BBQ company.

    from Yahoo Finance https://ift.tt/3j4P95N

  • Ex-Intel CEO Lists Lavish Silicon Valley Compound

    Ex-Intel CEO Lists Lavish Silicon Valley CompoundA nearly one-acre estate set on one of the most prime avenues in Atherton, arguably the Silicon Valley's most desirable residential neighborhood, recently popped up for sale with a $13.25 million pricetag. Tucked away behind walls and gates, the fully landscaped Tuscan-style spread is a bonafide compound with a three-level main house, detached guesthouse, and […]

    from Yahoo Finance https://ift.tt/3j6NH2S

  • Canadian Biotech IMV ‘Rapidly’ Progressing On Coronavirus Vaccine Development

    Canadian Biotech IMV 'Rapidly' Progressing On Coronavirus Vaccine DevelopmentImv Inc (NASDAQ: IMV) share are ripping higher on above-average volume following an update by the company on its coronavirus vaccine program.What Happened? The Dartmouth, Nova Scotia-based company said it's rapidly progressing in developing DPX-COVID-19, its vaccine candidate against SARS-CoV2.The company said it's working closely with regulators and collaborators to kickstart the Phase 1 study as quickly as possible. Health Canada has already approved the clinical trial design of the study, it added."The rapid progress in target selection, the vaccine formulation, manufacturing and preclinical results so far not only demonstrate the potential of our delivery platform, but also build on our previously reported clinical data from a similarly designed vaccine against RSV, the respiratory syncytial virus," said Frederic Ors, CEO of IMV.What's Next? IMV plans to conduct the early-stage study as a randomized controlled study, assessing the safety and immunogenicity of two doses of DPX-COVID-19, in 84 healthy adults across two age cohorts – adults, ages 18-55 years and ages 56 and above.IMV said multiple batches of DPX-COVID-19 have been successfully produced.The Phase 1 study is planned for the fall. Contingent on positive results from the study, the company plans to initiate Phase 2 trials in the second half of the year.IMV shares were rallying 69% to $5.07 at the time of publication.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See more from Benzinga * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant * The Week Ahead In Biotech: ASCO Presentations In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2WhwU34

  • Is Apple (AAPL) Stock Worth Your Attention Right Now?

    Is Apple (AAPL) Stock Worth Your Attention Right Now?On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

    from Yahoo Finance https://ift.tt/3gZzjY2

  • Were Hedge Funds Right About Warming Up To The Kraft Heinz Company (KHC)?

    Were Hedge Funds Right About Warming Up To The Kraft Heinz Company (KHC)?How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

    from Yahoo Finance https://ift.tt/30ejVjM

  • Moderna expects to start late-stage COVID-19 vaccine trial on July 27

    Moderna expects to start late-stage COVID-19 vaccine trial on July 27Moderna Inc said on Tuesday it plans to start a late stage clinical trial for its COVID-19 vaccine candidate on or around July 27, according to its listing for the phase 3 study at clinicaltrials.gov. Moderna said it will conduct the trial at 87 study locations, all in the United States. The experimental vaccine will be tested in 30 states and Washington, D.C. Around half of the study locations are in hard-hit states like Texas, California, Florida, Georgia, Arizona and North and South Carolina.

    from Yahoo Finance https://ift.tt/2DEgXgV

  • Why Bristol-Myers Squibb (BMY) Stock is a Compelling Investment Case

    Why Bristol-Myers Squibb (BMY) Stock is a Compelling Investment CaseOn July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

    from Yahoo Finance https://ift.tt/30595N4

  • Why Ad Boycott Won’t End Facebook’s (FB) Rally

    Why Ad Boycott Won’t End Facebook’s (FB) RallyOn July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

    from Yahoo Finance https://ift.tt/2Om4osT